About CORONA REMEDIES LIMITED
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in developing, manufacturing, and marketing prescription-based healthcare products. The company operates across key therapeutic segments including women’s healthcare, cardiology, diabetology, pain management, urology, gastrointestinal care, respiratory, and nutrition. As of June 30, 2025, the company offers 71 brands across multiple therapy categories and has built a strong presence in the Indian Pharmaceutical Market (IPM). Corona Remedies has a large pan-India marketing and distribution network, operated through 2,671 medical representatives across 22 states, enabling deep penetration and strong engagement with hospitals and healthcare professionals. The company operates two manufacturing facilities in Gujarat with a combined installed formulation capacity of 1,285.44 million units per annum, compliant with quality and Good Manufacturing Practice (GMP) standards. With a strong focus on innovation and specialized pharmaceutical products, Corona Remedies continues to expand its footprint in chronic and high-margin therapeutic categories.
Why To Invest in CORONA REMEDIES LIMITED
Fast-growing Industry Position: Corona Remedies is the second fastest-growing company among the top 30 Indian pharma companies (based on domestic sales, MAT June 2022–June 2025).
Strong Financial Growth: Revenue increased by 18% and profit after tax surged by 65% between FY 2024 and FY 2025, reflecting strong operational performance.
Diverse High-Margin Product Portfolio: Focus on chronic therapies such as cardio-diabetic and women’s health enables higher margins and long-term customer retention.
Strong Distribution Network: Presence across India with a large field force and established doctor-hospital relationships strengthens brand recall and market penetration.
Healthy Return Ratios: Strong financial indicators including ROE of 27.50%, ROCE of 41.32%, and low debt-to-equity ratio of 0.10 indicate financial stability.
Proven Management and R&D Capabilities: The leadership team brings industry expertise and the company continues to invest in innovation and differentiated solutions.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Explore Other Products
